December 2025

Lilly Becomes First Drugmaker to Hit $1 Trillion Valuation on Weight-Loss Demand

Eli Lilly recently surpassed a $1 trillion market capitalization amid increased demand for its weight-loss innovation. Kevin Gade, COO at Bahl & Gaynor, noted that the milestone reflects the significant role the company’s innovations have played in the healthcare market.

Kevin T. Gade
Chief Operating Officer
Principal & Portfolio Manager
[email protected]

To read more about this historic milestone, please follow the link HERE to the full article.

You're Leaving

You are now leaving the Bahl & Gaynor main website and entering into the Active ETFs website. By continuing to this link, we are not making any representation, warranty, or endorsement about the website and we are not providing you with investment advice or offering securities for sale to you.